Lyra Therapeutics, Inc. — Director's Dealing 2025

Jul 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2025-07-10

Reporting Person: Cavalier Jason (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-10	Common Stock	S	684	$8.91	Disposed	519316	Direct

Footnotes

F1: Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.